Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Caribou Biosciences, Inc. (CRBU)
USD1.74
-0.02 (-0.86%)
US NASDAQ Healthcare Biotechnology
Address
2929 7th Street 94710
Berkeley, CA, US
Berkeley, CA, US
CEO
Rachel E. Haurwitz
Website
cariboubio.com
IPO
2021-07-23
CIK 1619856 ISIN US1420381089
Description
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
News Sentiment (7d)
Based on only 1 article — low confidence
- Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.74
-0.02 (-0.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.37
Float Shares
88.29M
Free Float %
89.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +6.84% | +4.10% | +28.48% | +2.01% | +27.67% | +159.33% | -54.89% | -87.56% | -87.56% | -87.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
1.74
Low
3.00
+72.9%
Consensus
5.00
+188.2%
Median
5.00
+188.2%
High
7.00
+303.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
7.00
+303.5%
|
| All Time | 2 |
5.00
+188.2%
|
Quality scores
Altman Z-Score
-5.01
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+11.7% ★ Q1'26: +1.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+3.6% Q1'26: +39.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,199.4% Q1'26: -1,128.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,220.5% Q1'26: -1,096.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-1,353.6% Q1'26: -927.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.4% Q1'26: +3.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.21× Q1'26: -0.26× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.60M
est: 10.94M (-12.3%)
|
13.85M
est: 12.43M (+11.4%)
|
34.48M
est: 33.11M (+4.1%)
|
9.99M
est: 10.26M (-2.6%)
|
11.16M
est: 9.39M (+18.8%)
|
23.61M
5.90M – 59.03M
+151.5% YoY
|
27.05M
7.06M – 47.04M
+14.6% YoY
|
30.46M
8.98M – 75.63M
+12.6% YoY
|
49.88M
14.70M – 123.84M
+63.7% YoY
|
130.88M
38.57M – 324.96M
+162.4% YoY
|
| EBITDA |
-65.61M
est: -10.94M (-499.7%)
|
-95.71M
est: -12.43M (-669.9%)
|
-112.53M
est: -33.11M (-239.8%)
|
-162.69M
est: -10.26M (-1,485.6%)
|
-132.55M
est: -9.39M (-1,311.6%)
|
-23.61M
-59.03M – -5.90M
-151.5% YoY
|
-27.05M
-47.04M – -7.06M
-14.6% YoY
|
-30.46M
-75.63M – -8.98M
-12.6% YoY
|
-49.88M
-123.84M – -14.70M
-63.7% YoY
|
-130.88M
-324.96M – -38.57M
-162.4% YoY
|
| EBIT |
-66.59M
est: -10.94M (-508.7%)
|
-99.35M
est: -12.43M (-699.2%)
|
-116.06M
est: -33.11M (-250.5%)
|
-166.62M
est: -10.26M (-1,523.9%)
|
-136.19M
est: -9.39M (-1,350.4%)
|
-23.61M
-59.03M – -5.90M
-151.5% YoY
|
-27.05M
-47.04M – -7.06M
-14.6% YoY
|
-30.46M
-75.63M – -8.98M
-12.6% YoY
|
-49.88M
-123.84M – -14.70M
-63.7% YoY
|
-130.88M
-324.96M – -38.57M
-162.4% YoY
|
| Net Income |
-66.92M
est: -191.61M (+65.1%)
|
-99.42M
est: -111.20M (+10.6%)
|
-102.07M
est: -123.44M (+17.3%)
|
-149.11M
est: -151.10M (+1.3%)
|
-148.13M
est: -145.03M (-2.1%)
|
-96.22M
-122.53M – -69.90M
+33.7% YoY
|
-120.32M
-123.20M – -117.45M
-25.1% YoY
|
-145.83M
-181.96M – -109.70M
-21.2% YoY
|
-196.82M
-576.25M – -16.37M
-35.0% YoY
|
-224.37M
-656.91M – -18.66M
-14.0% YoY
|
| SGA |
23.34M
est: 26.43M (-11.7%)
|
38.02M
est: 30.03M (+26.6%)
|
38.46M
est: 94.96M (-59.5%)
|
46.46M
est: 29.42M (+57.9%)
|
37.91M
est: 26.93M (+40.8%)
|
67.71M
16.93M – 169.28M
+151.5% YoY
|
77.56M
20.23M – 134.89M
+14.6% YoY
|
87.35M
25.74M – 216.88M
+12.6% YoY
|
143.02M
42.16M – 355.12M
+63.7% YoY
|
375.30M
110.62M – 931.85M
+162.4% YoY
|
| EPS |
-1.11
est: -2.12 (+47.7%)
|
-1.64
est: -1.69 (+3.0%)
|
-1.38
est: -1.40 (+1.5%)
|
-1.65
est: -1.66 (+0.5%)
|
-1.59
est: -1.59 (-0.2%)
|
-1.16
-1.31 – -0.75
+27.2% YoY
|
-1.28
-1.32 – -1.26
-11.2% YoY
|
-1.56
-1.95 – -1.17
-21.7% YoY
|
-2.11
-6.17 – -0.18
-34.9% YoY
|
-2.40
-7.03 – -0.20
-14.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-99.64M
OE per share TTM
-1.06
Owner's Yield
-53.58%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
156.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
28
Total invested
5.36M
Insider transactions (90d)
0
Beneficial owners (>5%)
43
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Avidity Capital Partners (GP) LLC | 6.36M | 7.20% | — | 6.36M | — | 6.36M | OO | Delaware | 2024-01-08 | ↗ |
| 2 | Avidity Capital Partners Fund (GP) LP | 6.36M | 7.20% | — | 6.36M | — | 6.36M | PN, OO | Delaware | 2024-01-08 | ↗ |
| 3 | Avidity Partners Management (GP) LLC | 6.36M | 7.20% | — | 6.36M | — | 6.36M | OO | Delaware | 2024-01-08 | ↗ |
| 4 | Avidity Partners Management LP | 6.36M | 7.20% | — | 6.36M | — | 6.36M | IA, PN | Delaware | 2024-01-08 | ↗ |
| 5 | David Witzke | 6.36M | 7.20% | — | 6.36M | — | 6.36M | IN | Delaware | 2024-01-08 | ↗ |
| 6 | Michael Gregory | 6.36M | 7.20% | — | 6.36M | — | 6.36M | IN | Delaware | 2024-01-08 | ↗ |
| 7 | BANK OF AMERICA CORP /DE/56-0906609 | 5.05M | 5.60% | — | 4.82M | — | 5.05M | HC | Delaware | 2024-11-14 | ↗ |
| 8 | (1) BlackRock, Inc. | 4.72M | 7.70% | 4.62M | — | 4.72M | — | HC | Delaware | 2023-02-03 | ↗ |
| 9 | PFIZER INC. | 4.69M | 7.10% | 4.69M | — | 4.69M | — | CO | Delaware | 2023-07-10 | ↗ |
| 10 | Avidity Master Fund LP | 4.69M | 5.30% | — | 4.69M | — | 4.69M | PN, OO | Delaware | 2024-01-08 | ↗ |
| 11 | Steven A. Cohen | 4.43M | 5.00% | — | 4.43M | — | — | IN | Delaware | 2024-02-23 | ↗ |
| 12 | Point72 Asset Management, L.P. | 3.96M | 4.50% | — | 3.96M | — | — | PN | Delaware | 2024-02-23 | ↗ |
| 13 | Point72 Capital Advisors, Inc. | 3.96M | 4.50% | — | 3.96M | — | — | CO | Delaware | 2024-02-23 | ↗ |
| 14 | 2 | 3.61M | 4.50% | — | 3.61M | — | 3.61M | PN | Delaware | 2023-07-20 | ↗ |
| 15 | STATE STREET CORPORATION | 3.20M | 5.24% | — | 3.14M | — | 3.20M | HC | — | 2023-02-03 | ↗ |
| 16 | Andrew J. M. Spokes | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 17 | David T. Kim | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 18 | John R. Warren | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 19 | Mark C. Wehrly | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 20 | Michael B. Fisch | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 21 | Michael G. Linn | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 22 | Philip D. Dreyfuss | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 23 | Rajiv A. Patel | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 24 | Richard B. Fried | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 25 | Thomas G. Roberts, Jr. | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 26 | William Seybold | 2.96M | 4.90% | — | 2.96M | — | — | IN | — | 2022-02-11 | ↗ |
| 27 | Farallon Capital Management, L.L.C. | 2.43M | 4.00% | — | 2.43M | — | — | OO | — | 2022-02-11 | ↗ |
| 28 | Zone III Healthcare Holdings, LLC | 2.43M | 4.00% | — | 2.43M | — | — | OO | — | 2022-02-11 | ↗ |
| 29 | E. I. du Pont de Nemours and Company | 2.06M | 3.39% | 2.06M | — | 2.06M | — | CO | Delaware | 2022-06-01 | ↗ |
| 30 | Farallon Partners, L.L.C. | 499.3K | 0.80% | — | 499.3K | — | — | OO | — | 2022-02-11 | ↗ |
| 31 | 72 Investment Holdings, LLC | 474.1K | 0.50% | — | 474.1K | — | — | OO | Delaware | 2024-02-23 | ↗ |
| 32 | Differentiated Ventures Investments, LLC | 474.1K | 0.50% | — | 474.1K | — | — | OO | Delaware | 2024-02-23 | ↗ |
| 33 | Point72 Biotech Private Investments, LLC | 474.1K | 0.50% | — | 474.1K | — | — | OO | Delaware | 2024-02-23 | ↗ |
| 34 | Farallon Capital Offshore Investors II, L.P. | 209.2K | 0.30% | — | 209.2K | — | — | PN | — | 2022-02-11 | ↗ |
| 35 | Farallon Capital Institutional Partners, L.P. | 157.2K | 0.30% | — | 157.2K | — | — | PN | — | 2022-02-11 | ↗ |
| 36 | Farallon Capital Partners, L.P. | 66.6K | 0.10% | — | 66.6K | — | — | PN | — | 2022-02-11 | ↗ |
| 37 | Farallon Capital F5 Master I, L.P. | 36.0K | 0.10% | — | 36.0K | — | — | PN | — | 2022-02-11 | ↗ |
| 38 | Farallon F5 (GP), L.L.C. | 36.0K | 0.10% | — | 36.0K | — | — | OO | — | 2022-02-11 | ↗ |
| 39 | Farallon Capital Institutional Partners II, L.P. | 25.6K | 0.00% | — | 25.6K | — | — | PN | — | 2022-02-11 | ↗ |
| 40 | Farallon Institutional (GP) V, L.L.C. | 18.9K | 0.00% | — | 18.9K | — | — | OO | — | 2022-02-11 | ↗ |
| 41 | Four Crossings Institutional Partners V, L.P. | 18.9K | 0.00% | — | 18.9K | — | — | PN | — | 2022-02-11 | ↗ |
| 42 | Farallon Capital Institutional Partners III, L.P. | 14.3K | 0.00% | — | 14.3K | — | — | PN | — | 2022-02-11 | ↗ |
| 43 | Farallon Capital (AM) Investors, L.P. | 7.5K | 0.00% | — | 7.5K | — | — | PN | — | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
28
-99 vs prev Q
New positions
3
Closed positions
97
Increased
7
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 112.5K +112.5K (+100.0%) | 178.88M +178.9M (+100.0%) | 0.12% +0.121 pp | 0.15% +0.153 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 2 | PFIZER INC | 4.69M +— (+0.0%) | 7.46M -3.5M (-31.8%) | 5.03% -0.014 pp | 3.15% +0.656 pp | USD1.59 +0.0% | 5 qtrs — |
| 3 | VANGUARD GROUP INC | 4.30M +77.3K (+1.8%) | 6.84M -3.0M (-30.5%) | 4.61% +0.070 pp | 0.00% +0.000 pp | USD9.49 -83.2% | 18 qtrs — |
| 4 | KYNAM CAPITAL MANAGEMENT, LP | 2.50M -564.5K (-18.4%) | 3.98M -3.2M (-44.3%) | 2.68% -0.614 pp | 0.25% -0.278 pp | USD2.53 -37.2% | 10 qtrs — |
| 5 | BLACKROCK, INC. | 2.14M +681.7K (+46.7%) | 3.40M +4.0K (+0.1%) | 2.29% +0.726 pp | 0.00% +0.000 pp | USD1.84 -13.6% | 6 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 1.64M +859.4K (+110.1%) | 2.61M +789.0K (+43.4%) | 1.76% +0.919 pp | 0.00% +0.002 pp | USD1.59 +0.0% | 3 qtrs — |
| 7 | ABRDN PLC | 1.39M +— (+0.0%) | 2.21M -1.0M (-31.8%) | 1.49% -0.004 pp | 0.00% -0.002 pp | USD2.17 -26.7% | 9 qtrs — |
| 8 | TWO SIGMA ADVISERS, LP | 1.12M -111.7K (-9.1%) | 1.77M -1.1M (-38.0%) | 1.20% -0.124 pp | 0.00% -0.002 pp | USD1.70 -6.5% | 10 qtrs — |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.03M +585.8K (+131.5%) | 1.64M +601.6K (+57.9%) | 1.11% +0.627 pp | 0.00% +0.000 pp | USD1.64 -3.0% | 17 qtrs — |
| 10 | TWO SIGMA INVESTMENTS, LP | 1.02M +236.5K (+30.2%) | 1.62M -203.8K (-11.2%) | 1.09% +0.251 pp | 0.00% 0.000 pp | USD2.06 -22.8% | 13 qtrs — |
| 11 | DIMENSIONAL FUND ADVISORS LP | 1.01M -204.3K (-16.9%) | 1.60M -1.2M (-43.3%) | 1.08% -0.223 pp | 0.00% 0.000 pp | USD4.53 -64.9% | 13 qtrs — |
| 12 | BANK OF AMERICA CORP /DE/ | 993.2K -81.3K (-7.6%) | 1.58M -924.3K (-36.9%) | 1.06% -0.090 pp | 0.00% 0.000 pp | USD2.64 -39.8% | 18 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 976.8K -8.3K (-0.8%) | 1.55M -742.6K (-32.3%) | 1.05% -0.012 pp | 0.00% 0.000 pp | USD9.11 -82.5% | 18 qtrs — |
| 14 | PFM HEALTH SCIENCES, LP | 957.8K -401.0K (-29.5%) | 1.52M -1.6M (-51.9%) | 1.03% -0.434 pp | 0.15% -0.092 pp | USD13.06 -87.8% | 18 qtrs — |
| 15 | MARSHALL WACE, LLP | 881.1K +755.3K (+600.2%) | 1.40M +1.1M (+377.8%) | 0.94% +0.809 pp | 0.00% +0.001 pp | USD1.70 -6.5% | 2 qtrs — |
| 16 | JACOBS LEVY EQUITY MANAGEMENT, INC | 824.3K +475.2K (+136.1%) | 1.31M +497.3K (+61.1%) | 0.88% +0.508 pp | 0.01% +0.002 pp | USD1.54 +3.2% | 5 qtrs — |
| 17 | MILLENNIUM MANAGEMENT LLC | 767.0K -2.4M (-76.2%) | 1.22M -6.3M (-83.7%) | 0.82% -2.635 pp | 0.00% -0.003 pp | USD2.00 -20.5% | 18 qtrs — |
| 18 | FMR LLC | 726.0K -3.0K (-0.4%) | 1.15M -544.3K (-32.0%) | 0.78% -0.006 pp | 0.00% +0.000 pp | USD21.12 -92.5% | 18 qtrs — |
| 19 | MAVERICK CAPITAL LTD | 652.5K +— (+0.0%) | 1.04M -482.9K (-31.8%) | 0.70% -0.002 pp | 0.01% -0.009 pp | USD23.87 -93.3% | 18 qtrs — |
| 20 | UBS GROUP AG | 637.7K +318.5K (+99.7%) | 1.01M +270.1K (+36.3%) | 0.68% +0.340 pp | 0.00% +0.000 pp | USD1.93 -17.6% | 18 qtrs — |
| 21 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 581.8K -594.0 (-0.1%) | 925.0K -432.0K (-31.8%) | 0.62% -0.002 pp | 0.00% -0.001 pp | USD0.91 +74.7% | 4 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 555.6K -2.8K (-0.5%) | 883.4K -417.8K (-32.1%) | 0.60% -0.005 pp | 0.00% 0.000 pp | USD8.21 -80.6% | 18 qtrs — |
| 23 | CITADEL ADVISORS LLC | 515.4K +250.3K (+94.4%) | 819.5K +201.8K (+32.7%) | 0.55% +0.268 pp | 0.00% +0.000 pp | USD1.47 +8.2% | 3 qtrs — |
| 24 | GOLDMAN SACHS GROUP INC | 489.1K +244.3K (+99.8%) | 777.7K +207.3K (+36.3%) | 0.52% +0.261 pp | 0.00% +0.000 pp | USD2.56 -37.9% | 17 qtrs — |
| 25 | 72 INVESTMENT HOLDINGS, LLC | 474.1K +— (+0.0%) | 753.8K -350.8K (-31.8%) | 0.51% -0.001 pp | 1.49% -0.135 pp | USD23.87 -93.3% | 18 qtrs — |
| 26 | DEKABANK DEUTSCHE GIROZENTRALE | 130.0K +— (+0.0%) | 724.0K +8.0K (+1.1%) | 0.14% 0.000 pp | 0.00% +0.000 pp | USD5.73 -72.3% | 9 qtrs — |
| 27 | STATE STREET CORP | 423.3K +37.0K (+9.6%) | 673.0K -227.0K (-25.2%) | 0.45% +0.039 pp | 0.00% +0.000 pp | USD5.06 -68.6% | 18 qtrs — |
| 28 | XTX TOPCO LTD | 413.4K -28.2K (-6.4%) | 657.3K -371.5K (-36.1%) | 0.44% -0.032 pp | 0.02% -0.036 pp | USD2.07 -23.2% | 3 qtrs — |
| 29 | POINT72 ASSET MANAGEMENT, L.P. | 403.9K +115.4K (+40.0%) | 642.3K -30.1K (-4.5%) | 0.43% +0.123 pp | 0.00% 0.000 pp | USD3.41 -53.4% | 18 qtrs — |
| 30 | GREEN ALPHA ADVISORS, LLC | 375.1K +11.4K (+3.1%) | 596.5K -250.9K (-29.6%) | 0.40% +0.011 pp | 0.55% -0.272 pp | USD2.14 -25.7% | 18 qtrs — |
| 31 | GSA CAPITAL PARTNERS LLP | 371.4K +371.4K (+100.0%) | 590.0K +590.0K (+100.0%) | 0.40% +0.398 pp | 0.05% +0.051 pp | USD1.59 +0.0% | 4 qtrs — |
| 32 | MORGAN STANLEY | 298.5K -59.8K (-16.7%) | 474.5K -360.1K (-43.1%) | 0.32% -0.065 pp | 0.00% +0.000 pp | USD2.59 -38.6% | 18 qtrs — |
| 33 | JANE STREET GROUP, LLC | 295.7K -183.8K (-38.3%) | 470.1K -647.0K (-57.9%) | 0.32% -0.198 pp | 0.00% 0.000 pp | USD1.66 -4.2% | 11 qtrs — |
| 34 | BRUCE & CO., INC. | 250.0K +— (+0.0%) | 397.5K -185.0K (-31.8%) | 0.27% -0.001 pp | 0.12% -0.057 pp | USD3.72 -57.3% | 12 qtrs — |
| 35 | MILESTONE ASSET MANAGEMENT, LLC | 231.8K +55.8K (+31.7%) | 368.6K -41.4K (-10.1%) | 0.25% +0.059 pp | 0.07% -0.008 pp | USD1.34 +18.7% | 7 qtrs — |
| 36 | NORTHERN TRUST CORP | 217.7K +12.7K (+6.2%) | 346.2K -131.6K (-27.5%) | 0.23% +0.013 pp | 0.00% +0.000 pp | USD10.35 -84.6% | 18 qtrs — |
| 37 | QUBE RESEARCH & TECHNOLOGIES LTD | 204.7K +159.5K (+353.3%) | 325.4K +220.2K (+209.3%) | 0.22% +0.171 pp | 0.00% +0.000 pp | USD1.75 -9.1% | 2 qtrs — |
| 38 | OMERS ADMINISTRATION CORP | 178.1K +178.1K (+100.0%) | 283.2K +283.2K (+100.0%) | 0.19% +0.191 pp | 0.00% +0.002 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 39 | QUADRATURE CAPITAL LTD | 159.3K +159.3K (+100.0%) | 253.3K +253.3K (+100.0%) | 0.17% +0.171 pp | 0.00% +0.003 pp | USD1.59 +0.0% | 3 qtrs — |
| 40 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 148.5K +— (+0.0%) | 236.1K -109.9K (-31.8%) | 0.16% -0.001 pp | 0.00% -0.002 pp | USD1.77 -10.2% | 6 qtrs — |
| 41 | WELLS FARGO & COMPANY/MN | 141.9K +116.1K (+449.0%) | 225.7K +165.5K (+274.7%) | 0.15% +0.124 pp | 0.00% +0.000 pp | USD1.71 -7.0% | 18 qtrs — |
| 42 | AMERICAN CENTURY COMPANIES INC | 112.5K +30.7K (+37.5%) | 178.8K -11.8K (-6.2%) | 0.12% +0.033 pp | 0.00% +0.000 pp | USD2.13 -25.4% | 2 qtrs — |
| 43 | GRAHAM CAPITAL MANAGEMENT, L.P. | 107.3K -21.1K (-16.4%) | 170.5K -128.5K (-43.0%) | 0.12% -0.023 pp | 0.00% -0.001 pp | USD2.33 -31.8% | 4 qtrs — |
| 44 | SIREN, L.L.C. | 105.3K +— (+0.0%) | 167.5K -78.0K (-31.8%) | 0.11% 0.000 pp | 0.01% -0.005 pp | USD1.96 -18.9% | 6 qtrs — |
| 45 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 85.2K +85.2K (+100.0%) | 135.5K +135.5K (+100.0%) | 0.09% +0.091 pp | 0.00% +0.000 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 46 | AMERIPRISE FINANCIAL INC | 85.1K -250.0 (-0.3%) | 135.3K -63.6K (-32.0%) | 0.09% -0.001 pp | 0.00% +0.000 pp | USD1.59 +0.0% | 5 qtrs — |
| 47 | KEYSTONE FINANCIAL GROUP | 80.5K +16.5K (+25.8%) | 128.0K +47.3K (+58.7%) | 0.09% +0.018 pp | 0.01% +0.003 pp | USD1.47 +8.2% | 5 qtrs — |
| 48 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 77.7K +77.7K (+100.0%) | 123.5K +123.5K (+100.0%) | 0.08% +0.083 pp | 0.00% +0.001 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 49 | CITIGROUP INC | 74.6K +73.0K (+4,646.7%) | 118.6K +114.9K (+3,139.6%) | 0.08% +0.078 pp | 0.00% +0.000 pp | USD1.64 -3.0% | 18 qtrs — |
| 50 | ACADIAN ASSET MANAGEMENT LLC | 59.7K +59.7K (+100.0%) | 94.0K +94.0K (+100.0%) | 0.06% +0.064 pp | 0.00% +0.000 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 51 | NELSON CAPITAL MANAGEMENT, LLC | 58.7K -26.3K (-31.0%) | 93.3K -104.8K (-52.9%) | 0.06% -0.029 pp | 0.01% -0.013 pp | USD6.54 -75.7% | 16 qtrs — |
| 52 | SQUAREPOINT OPS LLC | 55.9K +31.8K (+132.0%) | 88.9K +32.8K (+58.3%) | 0.06% +0.034 pp | 0.00% +0.000 pp | USD1.45 +9.7% | 3 qtrs — |
| 53 | COMMONWEALTH EQUITY SERVICES, LLC | 45.9K -1.0K (-2.2%) | 73.0K -36.0K (-33.0%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD4.36 -63.5% | 8 qtrs — |
| 54 | JEFFERIES FINANCIAL GROUP INC. | 44.8K -2.4K (-5.0%) | 71.3K -38.7K (-35.2%) | 0.05% -0.003 pp | 0.00% 0.000 pp | USD2.33 -31.8% | 2 qtrs — |
| 55 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 44.2K +44.2K (+100.0%) | 70.2K +70.2K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.002 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 56 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 42.2K +— (+0.0%) | 67.1K -31.3K (-31.8%) | 0.05% 0.000 pp | 0.00% 0.000 pp | USD1.47 +8.2% | 5 qtrs — |
| 57 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 42.1K -73.0 (-0.2%) | 67.0K -31.3K (-31.9%) | 0.05% 0.000 pp | 0.00% 0.000 pp | USD1.35 +17.8% | 5 qtrs — |
| 58 | RBF CAPITAL, LLC | 40.0K -40.0K (-50.0%) | 63.6K -122.8K (-65.9%) | 0.04% -0.043 pp | 0.00% -0.006 pp | USD1.26 +26.2% | 3 qtrs — |
| 59 | MAN GROUP PLC | 36.7K +36.7K (+100.0%) | 58.4K +58.4K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 60 | WILEY BROS.-AINTREE CAPITAL, LLC | 35.5K -8.6K (-19.6%) | 56.5K -46.4K (-45.1%) | 0.04% -0.009 pp | 0.00% 0.000 pp | USD1.26 +26.2% | 3 qtrs — |
| 61 | INVESCO LTD. | 35.1K +22.9K (+187.2%) | 55.8K +27.3K (+96.0%) | 0.04% +0.025 pp | 0.00% +0.000 pp | USD3.37 -52.8% | 16 qtrs — |
| 62 | HSBC HOLDINGS PLC | 34.5K +— (+0.0%) | 55.0K -23.3K (-29.7%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD1.63 -2.5% | 8 qtrs — |
| 63 | US BANCORP \DE\ | 34.3K +— (+0.0%) | 54.5K -25.4K (-31.8%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD2.33 -31.8% | 15 qtrs — |
| 64 | PRIME CAPITAL INVESTMENT ADVISORS, LLC | 33.9K -740.0 (-2.1%) | 54.0K -26.8K (-33.2%) | 0.04% -0.001 pp | 0.00% 0.000 pp | USD2.52 -36.9% | 12 qtrs — |
| 65 | ENVESTNET ASSET MANAGEMENT INC | 32.3K -6.5K (-16.7%) | 51.4K -39.0K (-43.1%) | 0.03% -0.007 pp | 0.00% +0.000 pp | USD1.31 +21.4% | 7 qtrs — |
| 66 | THRIVE WEALTH MANAGEMENT, LLC | 32.0K +— (+0.0%) | 50.9K -23.7K (-31.8%) | 0.03% 0.000 pp | 0.01% -0.004 pp | USD1.59 +0.0% | 9 qtrs — |
| 67 | CREDIT AGRICOLE S A | 29.0K +— (+0.0%) | 46.1K -21.5K (-31.8%) | 0.03% 0.000 pp | 0.00% 0.000 pp | USD2.33 -31.8% | 2 qtrs — |
| 68 | AQR CAPITAL MANAGEMENT LLC | 25.6K -35.8K (-58.4%) | 40.6K -102.4K (-71.6%) | 0.03% -0.039 pp | 0.00% 0.000 pp | USD1.07 +48.6% | 7 qtrs — |
| 69 | RUSSELL INVESTMENTS GROUP, LTD. | 24.3K +10.8K (+80.0%) | 38.7K +7.2K (+22.9%) | 0.03% +0.012 pp | 0.00% +0.000 pp | USD1.60 -0.6% | 7 qtrs — |
| 70 | BARCLAYS PLC | 21.7K -108.2K (-83.3%) | 34.5K -220.0K (-86.4%) | 0.02% -0.116 pp | 0.00% 0.000 pp | USD2.47 -35.6% | 16 qtrs — |
| 71 | TOWER RESEARCH CAPITAL LLC (TRC) | 20.4K +1.1K (+5.9%) | 32.4K -12.4K (-27.7%) | 0.02% +0.001 pp | 0.00% -0.001 pp | USD1.33 +19.5% | 18 qtrs — |
| 72 | NEXT CAPITAL MANAGEMENT LLC | 20.0K +— (+0.0%) | 31.8K -14.8K (-31.8%) | 0.02% 0.000 pp | 0.01% -0.005 pp | USD1.26 +26.2% | 3 qtrs — |
| 73 | LIBERTY WEALTH MANAGEMENT LLC | 19.5K +— (+0.0%) | 31.0K -14.4K (-31.8%) | 0.02% 0.000 pp | 0.00% -0.002 pp | USD2.33 -31.8% | 2 qtrs — |
| 74 | CREATIVE PLANNING | 18.5K -422.0 (-2.2%) | 29.4K -14.7K (-33.3%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD1.26 +26.2% | 3 qtrs — |
| 75 | HIGHTOWER ADVISORS, LLC | 16.9K +— (+0.0%) | 26.9K -12.5K (-31.8%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD1.50 +6.0% | 5 qtrs — |
| 76 | CETERA INVESTMENT ADVISERS | 15.8K +898.0 (+6.0%) | 25.1K -9.6K (-27.6%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD1.74 -8.6% | 7 qtrs — |
| 77 | BRONTE CAPITAL MANAGEMENT PTY LTD. | 15.6K +15.6K (+100.0%) | 24.8K +24.8K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.003 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 78 | LPL FINANCIAL LLC | 15.5K +5.2K (+50.8%) | 24.7K +693.0 (+2.9%) | 0.02% +0.006 pp | 0.00% +0.000 pp | USD2.08 -23.6% | 2 qtrs — |
| 79 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 15.2K +15.2K (+100.0%) | 24.2K +24.2K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.002 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 80 | ROYAL BANK OF CANADA | 14.9K -559.4K (-97.4%) | 24.0K -1.3M (-98.2%) | 0.02% -0.601 pp | 0.00% 0.000 pp | USD1.43 +11.2% | 18 qtrs — |
| 81 | MODERN WEALTH MANAGEMENT, LLC | 15.0K +5.0K (+50.0%) | 23.9K +550.0 (+2.4%) | 0.02% +0.005 pp | 0.00% +0.000 pp | USD1.14 +39.5% | 4 qtrs — |
| 82 | BANK OF NEW YORK MELLON CORP | 13.0K -1.1K (-7.8%) | 20.6K -12.1K (-37.1%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD9.26 -82.8% | 18 qtrs — |
| 83 | PINNACLE WEALTH MANAGEMENT ADVISORY GROUP, LLC | 12.9K +— (+0.0%) | 20.5K -9.5K (-31.8%) | 0.01% +0.000 pp | 0.00% -0.001 pp | USD5.43 -70.7% | 15 qtrs — |
| 84 | PINNACLE ASSOCIATES LTD | 12.9K +— (+0.0%) | 20.5K -9.5K (-31.8%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD5.43 -70.7% | 15 qtrs — |
| 85 | CAPITAL ADVISORY GROUP ADVISORY SERVICES, LLC | 12.3K +— (+0.0%) | 19.6K -9.1K (-31.8%) | 0.01% +0.000 pp | 0.01% -0.003 pp | USD1.33 +19.5% | 3 qtrs — |
| 86 | BUCKINGHAM STRATEGIC PARTNERS | 12.2K -35.0 (-0.3%) | 19.4K -9.1K (-32.0%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD1.50 +6.0% | 5 qtrs — |
| 87 | HBK SORCE ADVISORY LLC | 12.3K +— (+0.0%) | 19.4K -15.7K (-44.7%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD1.26 +26.2% | 3 qtrs — |
| 88 | J.W. COLE ADVISORS, INC. | 11.3K +— (+0.0%) | 17.9K -8.3K (-31.8%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD0.91 +74.7% | 4 qtrs — |
| 89 | ADVISOR GROUP HOLDINGS, INC. | 10.7K +1.4K (+14.6%) | 17.0K -1.7K (-9.3%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD1.57 +1.3% | 18 qtrs — |
| 90 | NEWEDGE ADVISORS, LLC | 10.4K +— (+0.0%) | 16.5K -7.7K (-31.8%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD4.11 -61.3% | 13 qtrs — |
| 91 | CHEVY CHASE TRUST HOLDINGS, LLC | 10.0K +— (+0.0%) | 15.9K -7.4K (-31.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.91 +74.7% | 4 qtrs — |
| 92 | ALLWORTH FINANCIAL LP | 9.4K +9.4K (+100.0%) | 15.0K +15.0K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD1.59 +0.0% | 3 qtrs — |
| 93 | CANADA PENSION PLAN INVESTMENT BOARD | 7.4K +7.4K (+100.0%) | 11.8K +11.8K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD1.59 +0.0% | 1 qtrs NEW |
| 94 | JPMORGAN CHASE & CO | 6.6K +6.6K (+100.0%) | 10.5K +10.5K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD1.59 +0.0% | 18 qtrs — |
| 95 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 4.5K +4.5K (+100.0%) | 7.2K +7.2K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD1.59 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 52 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AXS Green Alpha ETF NXTE | 0.74% | 423.0K | 1.00% |
| 2 | Global X - Genomics & Biotechnology ETF GNOM | 0.21% | 180.2K | 0.50% |
| 3 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 0.21% | 107.6K | 0.50% |
| 4 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.11% | 318.5K | 0.39% |
| 5 | iShares Micro-Cap ETF IWC | 0.04% | 593.7K | 0.60% |
| 6 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 282.3K | 0.20% |
| 7 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.01% | 60.8K | 0.40% |
| 8 | iShares Biotechnology ETF IBB | 0.01% | 1.23M | 0.44% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.01% | 9.8K | 0.19% |
| 10 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.68M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.80
Bullish
Ratio by volume
3.00
Bullish
Buys
19
Sells
5
Shares acquired
2.50M
Shares disposed
24.3K
Cash buys
—
Cash sales
5.00
Net activity
+2,472,383
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-25 | Kelly Timothy P | Officer | S-Sale | D | Common Stock | 6,228 | 1.93 | 12.0K | 73,125 | D | ↗ |
| 2026-02-24 | MCCLUNG BARBARA G | Officer | S-Sale | D | Common Stock | 6,938 | 1.96 | 13.6K | 481,564 | D | ↗ |
| 2026-02-24 | Khan Ruhi Ahmad | Officer | S-Sale | D | Common Stock | 6,938 | 1.96 | 13.6K | 104,998 | D | ↗ |
| 2026-02-24 | Kelly Timothy P | Officer | S-Sale | D | Common Stock | 3,147 | 1.96 | 6.2K | 79,353 | D | ↗ |
| 2026-02-24 | Albertson Tina M. | Officer | S-Sale | D | Common Stock | 1,066 | 1.96 | 2.1K | 68,523 | D | ↗ |
| 2026-02-20 | Zheng Ran | Director | A-Award | A | Option to purchase Common Stock | 45,000 | 1.80 | 81.0K | 45,000 | D | ↗ |
| 2026-02-20 | Whiting Nancy | Director | A-Award | A | Option to purchase Common Stock | 45,000 | 1.80 | 81.0K | 45,000 | D | ↗ |
| 2026-02-20 | Sacks Natalie | Director | A-Award | A | Option to purchase Common Stock | 45,000 | 1.80 | 81.0K | 45,000 | D | ↗ |
| 2026-02-20 | Ryali Sriram | Officer | A-Award | A | Common Stock | 55,000 | 0.00 | — | 72,360 | D | ↗ |
| 2026-02-20 | Richardson-Heron Dara | Director | A-Award | A | Option to purchase Common Stock | 45,000 | 1.80 | 81.0K | 45,000 | D | ↗ |
| 2026-02-20 | MCCLUNG BARBARA G | Officer | A-Award | A | Option to purchase Common Stock | 202,500 | 1.80 | 364.5K | 202,500 | D | ↗ |
| 2026-02-20 | Khan Ruhi Ahmad | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 111,936 | D | ↗ |
| 2026-02-20 | Kelly Timothy P | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 82,500 | D | ↗ |
| 2026-02-20 | JOHNSON DAVID LEE | Director | A-Award | A | Option to purchase Common Stock | 45,000 | 1.80 | 81.0K | 45,000 | D | ↗ |
| 2026-02-20 | Haurwitz Rachel E. | Director / Officer | A-Award | A | Common Stock | 151,700 | 0.00 | — | 447,150 | D | ↗ |
| 2026-02-20 | GUGGENHIME ANDREW | Director | A-Award | A | Option to purchase Common Stock | 45,000 | 1.80 | 81.0K | 45,000 | D | ↗ |
| 2026-02-20 | Braunstein Scott | Director | A-Award | A | Option to purchase Common Stock | 45,000 | 1.80 | 81.0K | 45,000 | D | ↗ |
| 2026-02-20 | Albertson Tina M. | Officer | A-Award | A | Option to purchase Common Stock | 247,500 | 1.80 | 445.5K | 247,500 | D | ↗ |
| 2025-03-14 | Haurwitz Rachel E. | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 1.02 | 20.4K | 3,369,395 | I | ↗ |
| 2025-02-21 | MCCLUNG BARBARA G | Officer | S-Sale | D | Common Stock | 3,564 | 1.35 | 4.8K | 443,502 | D | ↗ |
| 2025-02-21 | Khan Ruhi Ahmad | Officer | S-Sale | D | Common Stock | 3,564 | 1.35 | 4.8K | 66,936 | D | ↗ |
| 2025-02-21 | Kanner Steven | Officer | S-Sale | D | Common Stock | 3,564 | 1.35 | 4.8K | 431,556 | D | ↗ |
| 2025-02-20 | Zheng Ran | Director | A-Award | A | Option to purchase Common Stock | 40,500 | 1.41 | 57.1K | 40,500 | D | ↗ |
| 2025-02-20 | Whiting Nancy | Director | A-Award | A | Option to purchase Common Stock | 40,500 | 1.41 | 57.1K | 40,500 | D | ↗ |
| 2025-02-20 | Sacks Natalie | Director | A-Award | A | Option to purchase Common Stock | 40,500 | 1.41 | 57.1K | 40,500 | D | ↗ |
| 2025-02-20 | Richardson-Heron Dara | Director | A-Award | A | Option to purchase Common Stock | 40,500 | 1.41 | 57.1K | 40,500 | D | ↗ |
| 2025-02-20 | MCCLUNG BARBARA G | Officer | A-Award | A | Option to purchase Common Stock | 170,000 | 1.41 | 239.7K | 170,000 | D | ↗ |
| 2025-02-20 | Khan Ruhi Ahmad | Officer | A-Award | A | Common Stock | 37,500 | 0.00 | — | 70,500 | D | ↗ |
| 2025-02-20 | Kelly Timothy P | Officer | A-Award | A | Common Stock | 37,500 | 0.00 | — | 37,500 | D | ↗ |
| 2025-02-20 | Kanner Steven | Officer | A-Award | A | Option to purchase Common Stock | 170,000 | 1.41 | 239.7K | 170,000 | D | ↗ |
| 2025-02-20 | JOHNSON DAVID LEE | Director | A-Award | A | Option to purchase Common Stock | 40,500 | 1.41 | 57.1K | 40,500 | D | ↗ |
| 2025-02-20 | Haurwitz Rachel E. | Director / Officer | A-Award | A | Option to purchase Common Stock | 618,250 | 1.41 | 871.7K | 618,250 | D | ↗ |
| 2025-02-20 | GUGGENHIME ANDREW | Director | A-Award | A | Option to purchase Common Stock | 40,500 | 1.41 | 57.1K | 40,500 | D | ↗ |
| 2025-02-20 | Braunstein Scott | Director | A-Award | A | Option to purchase Common Stock | 40,500 | 1.41 | 57.1K | 40,500 | D | ↗ |
| 2025-02-20 | Albertson Tina M. | Officer | A-Award | A | Common Stock | 14,589 | 0.00 | — | 14,589 | D | ↗ |
| 2025-01-29 | Ryali Sriram | Officer | P-Purchase | A | Common Stock | 17,360 | 1.42 | 24.7K | 17,360 | D | ↗ |
| 2025-01-10 | Ryali Sriram | Officer | A-Award | A | Option to purchase Common Stock | 300,000 | 1.64 | 492.0K | 300,000 | D | ↗ |
| 2025-01-02 | Ryali Sriram | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-20 | Fischesser Ryan | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 118,854 | D | ↗ |
| 2024-09-27 | Fischesser Ryan | Officer | — | — | Option to purchase Common Stock | 13,065 | 4.11 | 53.7K | 0 | D | ↗ |
| 2024-08-19 | Albertson Tina M. | Officer | A-Award | A | Option to purchase Common Stock | 300,000 | 2.18 | 654.0K | 300,000 | — | ↗ |
| 2024-08-12 | Albertson Tina M. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-20 | Zheng Ran | Director | A-Award | A | Option to purchase Common Stock | 39,500 | 6.81 | 269.0K | 39,500 | — | ↗ |
| 2024-02-20 | Whiting Nancy | Director | A-Award | A | Option to purchase Common Stock | 39,500 | 6.81 | 269.0K | 39,500 | — | ↗ |
| 2024-02-20 | Sacks Natalie | Director | A-Award | A | Option to purchase Common Stock | 39,500 | 6.81 | 269.0K | 39,500 | — | ↗ |
| 2024-02-20 | Richardson-Heron Dara | Director | A-Award | A | Option to purchase Common Stock | 39,500 | 6.81 | 269.0K | 39,500 | — | ↗ |
| 2024-02-20 | O'Byrne Jason | Officer | A-Award | A | Common Stock | 33,000 | 0.00 | — | 59,224 | — | ↗ |
| 2024-02-20 | MCCLUNG BARBARA G | Officer | A-Award | A | Option to purchase Common Stock | 153,000 | 6.81 | 1.04M | 153,000 | — | ↗ |
| 2024-02-20 | Khan Ruhi Ahmad | Officer | A-Award | A | Common Stock | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2024-02-20 | Kanner Steven | Officer | A-Award | A | Common Stock | 33,000 | 0.00 | — | 387,037 | — | ↗ |
| 2024-02-20 | JOHNSON DAVID LEE | Director | A-Award | A | Option to purchase Common Stock | 39,500 | 6.81 | 269.0K | 39,500 | — | ↗ |
| 2024-02-20 | Haurwitz Rachel E. | Director / Officer | A-Award | A | Common Stock | 118,700 | 0.00 | — | 158,700 | — | ↗ |
| 2024-02-20 | GUGGENHIME ANDREW | Director | A-Award | A | Option to purchase Common Stock | 39,500 | 6.81 | 269.0K | 39,500 | — | ↗ |
| 2024-02-20 | Braunstein Scott | Director | A-Award | A | Option to purchase Common Stock | 39,500 | 6.81 | 269.0K | 39,500 | — | ↗ |
| 2024-02-06 | Kanner Steven | Officer | M-Exempt | A | Common Stock | 30,577 | 2.69 | 82.3K | 354,037 | — | ↗ |
| 2024-01-08 | Kelly Timothy P | Officer | A-Award | A | Option to purchase Common Stock | 300,000 | 5.74 | 1.72M | 300,000 | — | ↗ |
| 2024-01-01 | Kelly Timothy P | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-08 | Haurwitz Rachel E. | Director / Officer | M-Exempt | D | Option to purchase Common Stock | 10,000 | 2.96 | 29.6K | 96,350 | — | ↗ |
| 2023-03-20 | Haurwitz Rachel E. | Director / Officer | M-Exempt | D | Option to purchase Common Stock | 10,000 | 2.96 | 29.6K | 106,350 | — | ↗ |
| 2023-02-21 | Zheng Ran | Director | A-Award | A | Option to purchase Common Stock | 21,500 | 6.12 | 131.6K | 21,500 | — | ↗ |
| 2023-02-21 | Whiting Nancy | Director | A-Award | A | Option to purchase Common Stock | 21,500 | 6.12 | 131.6K | 21,500 | — | ↗ |
| 2023-02-21 | Sacks Natalie | Director | A-Award | A | Option to purchase Common Stock | 21,500 | 6.12 | 131.6K | 21,500 | — | ↗ |
| 2023-02-21 | Rizvi Syed Ali-aamir | Officer | A-Award | A | Option to purchase Common Stock | 131,000 | 6.12 | 801.7K | 131,000 | — | ↗ |
| 2023-02-21 | Richardson-Heron Dara | Director | A-Award | A | Option to purchase Common Stock | 21,500 | 6.12 | 131.6K | 21,500 | — | ↗ |
| 2023-02-21 | O'Byrne Jason | Officer | A-Award | A | Option to purchase Common Stock | 131,000 | 6.12 | 801.7K | 131,000 | — | ↗ |
| 2023-02-21 | MCCLUNG BARBARA G | Officer | A-Award | A | Option to purchase Common Stock | 131,000 | 6.12 | 801.7K | 131,000 | — | ↗ |
| 2023-02-21 | Khan Ruhi Ahmad | Officer | A-Award | A | Option to purchase Common Stock | 131,000 | 6.12 | 801.7K | 131,000 | — | ↗ |
| 2023-02-21 | Kanner Steven | Officer | A-Award | A | Option to purchase Common Stock | 131,000 | 6.12 | 801.7K | 131,000 | — | ↗ |
| 2023-02-21 | JOHNSON DAVID LEE | Director | A-Award | A | Option to purchase Common Stock | 21,500 | 6.12 | 131.6K | 21,500 | — | ↗ |
| 2023-02-21 | Haurwitz Rachel E. | Director / Officer | A-Award | A | Option to purchase Common Stock | 510,500 | 6.12 | 3.12M | 510,500 | — | ↗ |
| 2023-02-21 | GUGGENHIME ANDREW | Director | A-Award | A | Option to purchase Common Stock | 21,500 | 6.12 | 131.6K | 21,500 | — | ↗ |
| 2023-02-21 | Braunstein Scott | Director | A-Award | A | Option to purchase Common Stock | 21,500 | 6.12 | 131.6K | 21,500 | — | ↗ |
| 2023-01-19 | Rizvi Syed Ali-aamir | Officer | S-Sale | D | Common Stock | 5,627 | 6.31 | 35.5K | 59,373 | — | ↗ |
| 2022-12-02 | Kanner Steven | Officer | M-Exempt | A | Common Stock | 21,401 | 2.69 | 57.6K | 323,460 | — | ↗ |
| 2022-10-06 | Fischesser Ryan | Officer | M-Exempt | A | Common Stock | 2,839 | 4.11 | 11.7K | 116,044 | — | ↗ |
| 2022-09-15 | MCCLUNG BARBARA G | Officer | M-Exempt | D | Option to purchase Common Stock | 77 | 2.69 | 207.13 | 0 | — | ↗ |
| 2022-08-25 | Kanner Steven | Officer | S-Sale | D | Common Stock | 43,248 | 11.22 | 485.2K | 302,059 | — | ↗ |
| 2022-08-22 | Khan Ruhi Ahmad | Officer | A-Award | A | Option to purchase Common Stock | 70,000 | 9.90 | 693.0K | 70,000 | — | ↗ |
| 2022-08-22 | Fischesser Ryan | Officer | A-Award | A | Common Stock | 4,848 | 0.00 | — | 120,366 | — | ↗ |
| 2022-05-18 | JOHNSON DAVID LEE | Director | A-Award | A | Option to purchase Common Stock | 44,000 | 0.00 | — | 44,000 | — | ↗ |
| 2022-05-13 | Kanner Steven | Officer | M-Exempt | D | Option to purchase Common Stock | 68,306 | 1.81 | 123.6K | 3,534 | — | ↗ |
| 2022-05-11 | JOHNSON DAVID LEE | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-09 | Haurwitz Rachel E. | Director / Officer | M-Exempt | D | Option to purchase Common Stock | 10,000 | 2.96 | 29.6K | 116,350 | — | ↗ |
| 2022-05-05 | Fischesser Ryan | Officer | M-Exempt | A | Common Stock | 1,138 | 4.11 | 4.7K | 115,518 | — | ↗ |
| 2022-03-15 | Fischesser Ryan | Officer | M-Exempt | A | Common Stock | 1,136 | 2.69 | 3.1K | 112,106 | — | ↗ |
| 2022-03-04 | Kanner Steven | Officer | M-Exempt | A | Common Stock | 9,171 | 2.69 | 24.7K | 226,090 | — | ↗ |
| 2022-02-08 | O'Byrne Jason | Officer | M-Exempt | D | Option to purchase Common Stock | 24,336 | 4.11 | 100.0K | 412,865 | — | ↗ |
| 2022-01-26 | Haurwitz Rachel E. | Director / Officer | M-Exempt | D | Option to purchase Common Stock | 10,000 | 2.96 | 29.6K | 126,350 | — | ↗ |
| 2022-01-25 | Rizvi Syed Ali-aamir | Officer | A-Award | A | Option to purchase common stock | 161,250 | 10.64 | 1.72M | 161,250 | — | ↗ |
| 2022-01-18 | Rizvi Syed Ali-aamir | Officer | — | D | Common Stock | 0 | 0.00 | — | 5,000 | — | ↗ |
| 2022-01-11 | Fischesser Ryan | Officer | P-Purchase | A | Common Stock | 569 | 2.69 | 1.5K | 102,264 | — | ↗ |
| 2021-12-31 | Haurwitz Rachel E. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-20 | Zheng Ran | Director | A-Award | A | Option to purchase Common Stock | 13,750 | 15.16 | 208.5K | 13,750 | — | ↗ |
| 2021-12-20 | Whiting Nancy | Director | A-Award | A | Option to purchase Common Stock | 13,750 | 15.16 | 208.5K | 13,750 | — | ↗ |
| 2021-12-20 | Sacks Natalie | Director | A-Award | A | Option to purchase Common Stock | 27,500 | 15.16 | 416.9K | 27,500 | — | ↗ |
| 2021-12-20 | O'Byrne Jason | Officer | A-Award | A | Option to purchase Common Stock | 147,000 | 15.16 | 2.23M | 147,000 | — | ↗ |
| 2021-12-20 | MCCLUNG BARBARA G | Officer | A-Award | A | Option to purchase Common Stock | 147,000 | 15.16 | 2.23M | 147,000 | — | ↗ |
| 2021-12-20 | Kanner Steven | Officer | A-Award | A | Option to purchase Common Stock | 147,000 | 15.16 | 2.23M | 147,000 | — | ↗ |
| 2021-12-20 | Haurwitz Rachel E. | Director / Officer | A-Award | A | Option to purchase Common Stock | 411,000 | 15.16 | 6.23M | 411,000 | — | ↗ |
| 2021-12-20 | GUGGENHIME ANDREW | Director | A-Award | A | Option to purchase Common Stock | 27,500 | 15.16 | 416.9K | 27,500 | — | ↗ |
| 2021-12-20 | Fischesser Ryan | Officer | A-Award | A | Option to purchase Common Stock | 40,000 | 15.16 | 606.4K | 40,000 | — | ↗ |
| 2021-12-20 | Braunstein Scott | Director | A-Award | A | Option to purchase Common Stock | 27,500 | 15.16 | 416.9K | 27,500 | — | ↗ |
| 2021-12-07 | MCCLUNG BARBARA G | Officer | X-InTheMoney | D | Option to purchase Common Stock | 6,115 | 2.69 | 16.4K | 74,836 | — | ↗ |
| 2021-11-15 | Khan Ruhi Ahmad | Officer | A-Award | A | Option to purchase Common Stock | 225,000 | 21.73 | 4.89M | 225,000 | — | ↗ |
| 2021-11-11 | Richardson-Heron Dara | Director | A-Award | A | Option to purchase Common Stock | 44,000 | 20.52 | 902.9K | 44,000 | — | ↗ |
| 2021-11-08 | Khan Ruhi Ahmad | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-04 | Richardson-Heron Dara | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-20 | MCCLUNG BARBARA G | Officer | P-Purchase | A | Common Stock | 43 | 2.69 | 115.67 | 342,844 | — | ↗ |
| 2021-10-12 | Kanner Steven | Officer | P-Purchase | A | Common Stock | 99,548 | 1.81 | 180.2K | 199,719 | — | ↗ |
| 2021-10-11 | Fischesser Ryan | Officer | P-Purchase | A | Common Stock | 1,746 | 2.69 | 4.7K | 100,559 | — | ↗ |
| 2021-10-01 | Zheng Ran | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 22.31 | 981.6K | 44,000 | — | ↗ |
| 2021-09-24 | Zheng Ran | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-09-08 | Whiting Nancy | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 28.32 | 1.25M | 44,000 | — | ↗ |
| 2021-08-24 | Whiting Nancy | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-27 | FMR LLC | Other | C-Conversion | D | Series A-1 Preferred Stock | 805,707 | 0.00 | — | 0 | — | ↗ |
| 2021-07-22 | Sacks Natalie | Director | — | D | Stock Option (Right to Buy) | 36,360 | 2.68 | 97.4K | 0 | — | ↗ |
| 2021-07-22 | O'Byrne Jason | Officer | — | D | Stock Option (Right to Buy) | 437,201 | 4.11 | 1.80M | 0 | — | ↗ |
| 2021-07-22 | MCCLUNG BARBARA G | Officer | — | D | Stock Option (Right to Buy) | 90,127 | 2.68 | 241.5K | 0 | — | ↗ |
| 2021-07-22 | Long-McGie Jeffrey Stephen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-22 | Kanner Steven | Officer | — | D | Stock Option (Right to Buy) | 231,914 | 4.11 | 953.2K | 0 | — | ↗ |
| 2021-07-22 | Haurwitz Rachel E. | Director / Officer | — | D | Stock Option (Right to Buy) | 136,350 | 2.95 | 402.2K | 0 | — | ↗ |
| 2021-07-22 | GUGGENHIME ANDREW | Director | — | D | Stock Option (Right to Buy) | 87,440 | 5.27 | 460.8K | 0 | — | ↗ |
| 2021-07-22 | Fischesser Ryan | Officer | — | D | Stock Option (Right to Buy) | 27,270 | 4.11 | 112.1K | 0 | — | ↗ |
| 2021-07-22 | FMR LLC | 10% Owner | — | I | Series A-1 Preferred Stock | 1,464,775 | 0.00 | — | 0 | — | ↗ |
| 2021-07-22 | Braunstein Scott | Director | — | D | Stock Option (Right to Buy) | 87,440 | 5.27 | 460.8K | 0 | — | ↗ |
| 2016-05-11 | Caribou Therapeutics Holdco, LLC | 10% Owner | C-Conversion | A | Common Stock | 174,806 | 0.00 | — | 349,612 | — | ↗ |
| 2016-05-05 | Caribou Therapeutics Holdco, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 174,806 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-9.3K
Shares Outstanding
99.18M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Rachel Haurwitz, Ph.D. President and chief executive officer | 667.5K | 312.1K | 192.8K | 654.5K | — | 14.0K | 1.84M | 46.03% | ↗ |
| 2 | 2025 | Sriram Ryali, M.B.A. Chief financial officer | 483.2K | 164.9K | — | 367.4K | — | 14.0K | 1.03M | 35.69% | ↗ |
| 3 | 2025 | Barbara McClung, J.D. Chief legal officer | 502.0K | 170.7K | 52.9K | 180.0K | — | 14.0K | 919.6K | 25.32% | ↗ |
| 4 | 2024 | Rachel Haurwitz, Ph.D. President and chief executive officer | 508.7K | 310.4K | 808.3K | 2.57M | — | 13.8K | 4.21M | 80.23% | ↗ |
| 5 | 2024 | Tim Kelly, M.B.A. Chief technology officer | 475.0K | 241.3K | — | 1.18M | — | 13.8K | 1.91M | 61.84% | ↗ |
| 6 | 2024 | Barbara McClung, J.D. Chief legal officer | 485.1K | 169.8K | 224.7K | 719.5K | — | 13.8K | 1.61M | 58.54% | ↗ |
| 7 | 2024 | Steven Kanner, Ph.D. Chief scientific officer | 485.1K | 169.8K | 224.7K | 719.5K | — | 13.8K | 1.61M | 58.54% | ↗ |
| 8 | 2023 | Rachel Haurwitz, Ph.D. President and chief executive officer | 623.2K | 342.7K | — | 2.14M | — | 13.2K | 3.12M | 68.58% | ↗ |
| 9 | 2023 | Syed Rizvi, M.D. Former chief medical officer | 504.7K | 201.9K | — | 548.5K | — | 13.2K | 1.27M | 43.25% | ↗ |
| 10 | 2023 | Barbara McClung, J.D. Chief legal officer | 468.7K | 187.5K | — | 548.5K | — | 13.2K | 1.22M | 45.04% | ↗ |
| 11 | 2023 | Steven Kanner, Ph.D. Chief scientific officer | 468.7K | 187.5K | — | 548.5K | — | 13.2K | 1.22M | 45.04% | ↗ |
| 12 | 2022 | Syed Rizvi, M.D. Chief medical officer | 467.7K | 172.4K | 638.4K | 1.10M | — | 12.2K | 2.39M | 72.69% | ↗ |
| 13 | 2022 | Syed Rizvi, M.D. Former chief medical officer | 467.7K | 172.4K | 638.4K | 1.10M | — | 12.2K | 2.39M | 72.69% | ↗ |
| 14 | 2022 | Ruhi Khan, M.B.A. Chief business officer | 410.0K | 151.7K | — | 464.2K | — | 12.2K | 1.04M | 44.72% | ↗ |
| 15 | 2022 | Rachel Haurwitz, Ph.D. President and chief executive officer | 513.5K | 307.8K | — | — | — | 12.2K | 833.5K | 0.00% | ↗ |
| 16 | 2021 | Rachel Haurwitz, Ph.D. President and chief executive officer | 527.4K | 319.1K | — | 5.39M | — | 11.6K | 6.25M | 86.27% | ↗ |
| 17 | 2021 | Rachel E. Haurwitz, Ph.D. President and chief executive officer | 527.4K | 319.1K | — | 5.39M | — | 11.6K | 6.25M | 86.27% | ↗ |
| 18 | 2021 | Jason V. O'Byrne, M.B.A. Chief financial officer | 358.6K | 227.8K | — | 2.86M | — | — | 3.45M | 83.00% | ↗ |
| 19 | 2021 | Barbara G. McClung, J.D. Chief legal officer and corporate secretary | 414.4K | 182.4K | — | 2.13M | — | 11.6K | 2.74M | 77.82% | ↗ |
| 20 | 2020 | Rachel E. Haurwitz, Ph.D. President and chief executive officer | 450.0K | 202.5K | — | — | — | 11.4K | 663.9K | 0.00% | ↗ |
| 21 | 2020 | Barbara G. McClung, J.D. Chief legal officer and corporate secretary | 365.0K | 127.8K | — | — | — | 11.4K | 504.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rachel E. Haurwitz | Co-Founder, Chief Executive Officer, President & Director | 993.6K | — |
| Timothy Kelly | Chief Technology Officer | 730.1K | male |
| Barbara G. McClung | Chief Legal Officer & Corporate Secretary | 686.7K | female |
| Tina Albertson | Chief Medical Officer | 677.1K | — |
| Sriram Ryali | Chief Financial Officer | 663.5K | male |
| Ruhi A. Khan | Chief Business Officer | 573.9K | female |
| Ryan Fischesser | Interim Principal Accounting Officer & Controller | — | male |
| Reigin Zawadzki | Chief People Officer | — | female |
| Jennifer A. Doudna | Co-founder & Member of Scientific Advisory Board | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRBU
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
